Merck announces new biopharma heads for North America and China

MerckMerck, a leading science and technology company, today announced two appointments in two regions important for its biopharma business. Gary Zieziula will lead Merck's biopharma business in North America and Marc Horn will take the helm of the biopharma business in China.

Gary Zieziula (61) has been appointed President and Managing Director of the biopharma business in the U.S. and Canada, based in Rockland, Massachusetts, U.S., with immediate effect. In his role, he will be responsible for all areas of the company's business including driving overall strategic direction and maximizing growth across the region. Zieziula joined Merck in 2014 as Chief Commercial Officer in the U.S., having spent more than 30 years in the pharmaceutical industry, including senior level positions at MSD, Bristol Myers-Squibb, Roche and Amag Pharmaceuticals. Zieziula holds a Bachelor of Science degree from the State University of New York at Buffalo and an MBA from Canisius College.

"As we look to grow our biopharma business in North America, including our progress in oncology and immuno-oncology, Gary's vision, experience and customer-centric approach are critical to lead the company forward," said Simon Sturge, Chief Operating Officer at the Healthcare business of Merck, whom Zieziula will report to.

Zieziula's predecessor, Paris Panayiotopoulos, accepted a new position outside of Merck at the end of last year.

In the first nine months of 2015 net sales of Merck in North America amounted to € 1.9 billion, thereby accounting for 20% of Group sales. Healthcare sales in this region totalled € 1.1 billion in the first nine months of 2015. In the first nine months of 2015 Healthcare sales in North America represented two-thirds of Merck's total sales in the region.

Marc Horn (41) will head the biopharma business of Merck in China as of April 1, 2016, as a Managing Director based in Beijing. He is currently the regional Chief Financial Officer (CFO) of Merck responsible for Eastern Asia, comprising China, Hong Kong, Japan, South Korea and Taiwan, for the three business sectors Healthcare, Life Science and Performance Materials.

Horn has more than 16 years of management experience in finance in the pharmaceuticals and chemicals industry, including positions at Bayer and Lanxess in Germany, China and Singapore. Horn graduated from Otto-Friedrich University of Bamberg, Germany, and University of Maastricht, Netherlands, with a Master's degree in International Business Administration.

Allan Gabor, Mark Horn's predecessor, has been promoted to President of the Asian-Pacific region for Merck's biopharma business. In his new position, Horn will report to Gabor.

China is of importance to Merck currently and in future. Among others the company is building a € 80 million (650 million Yuan) pharmaceutical manufacturing plant in the Nantong Economical Technological Development Area (NETDA), in the Greater Shanghai region (Yangtze River Delta area). Completion of the facility, which will focus on bulk production and packaging of Glucophage, Concor and Euthyrox, is scheduled for 2016, with commercial production starting in 2017.

With an organic increase of 5.1%, sales in the Asia-Pacific region, where China is included, amounted to € 3.1 billion in the months January to September 2015. Representing a share of 33% of Group net sales, Asia-Pacific therefore became the Group's top-selling region. Healthcare sales from January to September 2015 in the Asia-Pacific region reached around € 1 billion, representing one-third of group sales in this region.

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2014, Merck generated sales of € 11.3 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Most Popular Now

FDA approves drug to treat ALS

The U.S. Food and Drug Administration today approved Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig's...

Read more

FDA approves first cancer treatment for any solid …

The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is th...

Read more

Sanofi and Regeneron announce FDA Approval of Kevz…

Sanofi and Regeneron Pharmaceuticals, Inc. have announced the U.S. Food and Drug Administration (FDA) approval of Kevzara® (sarilumab) for the treatment of adult patients...

Read more

AstraZeneca marks a key milestone with the ‘toppin…

AstraZeneca marks a key milestone in its successful move to Cambridge, UK, with the 'topping out' of its new, state-of-the-art, strategic R&D centre and global corporate ...

Read more

FDA approves first treatment for a form of Batten …

The U.S. Food and Drug Administration today approved Brineura (cerliponase alfa) as a treatment for a specific form of Batten disease. Brineura is the first FDA-approved ...

Read more

Abbott announces CE Mark and first use of the worl…

Abbott (NYSE: ABT) today announced CE Mark and first use of the new Confirm RxTM Insertable Cardiac Monitor (ICM), the world's first smartphone compatible ICM that will h...

Read more

Imfinzi significantly reduces the risk of disease …

AstraZeneca and MedImmune, its global biologics research and development arm, today announced positive results for the Phase III PACIFIC trial, a randomised, double-blind...

Read more

Antibiotic doxycycline may offer hope for treatmen…

A study published in the journal Scientific Reports suggests that doxycycline, an antibiotic used for over half a century against bacterial infections, can be prescribed ...

Read more

Novartis exercises exclusive option agreement with…

Novartis announced today that it has notified Conatus Pharmaceuticals Inc., of its exercise of the option to an exclusive license for the global development and commercia...

Read more

England's Cancer Drugs Fund 'failed to deliver mea…

Analysis of the drugs that were approved for use by the NHS Cancer Drugs Fund (CDF) in England has shown that the fund was not good value for patients and society and may...

Read more

High levels of exercise linked to nine years of le…

Despite their best efforts, no scientist has ever come close to stopping humans from aging. Even anti-aging creams can't stop Old Father Time. But new research from Brigh...

Read more

Vitamin A deficiency is detrimental to blood stem …

Many specialized cells, such as in the skin, gut or blood, have a lifespan of only a few days. Therefore, steady replenishment of these cells is indispensable. They arise...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]